Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker.
By combining their areas of expertise, Novo Nordisk A/S and Flagship Pioneering aim to create a portfolio of three to five therapeutic candidates for cardiovascular and/or rare diseases within three years. Flagship, the originator of 41 biotechnology firms, including Moderna, Inc